Adcetris
Active Ingredient(s): Brentuximab VedotinFDA Approved: * August 19, 2011
Pharm Company: * SEATTLE GENETICS
Category: Cancer
* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".
Adcetris Overview
Brentuximab vedotin (INN; trade name Adcetris) is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T cell non-Hodgkin lymphoma. It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL.[2] The drug is being jointly marketed by Millennium Pharmaceuticals outside the US and by Seattle Genetics in the US.[3&...
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Brentuximab_vedotin
Recent Adcetris Forums:
Be the first to start a discussion about this drug.Possible Dosages for this and Related Drugs:
Brentuximab Vedotin
- Injection: 50mg/vial
NDC Database Records for Adcetris: (1 result)
Sorted by National Drug Code- 51144-050 Adcetris 50 mg/10.5ml Intravenous Injection, Powder, Lyophilized, for Solution by Seattle Genetics, Inc.